Macrophage News and Research RSS Feed - Macrophage News and Research

A macrophage is a type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells.
Regulation of tumor microenvironment may offer alternate method for cancer treatment

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer. [More]
Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). [More]
New study explains why statins are more beneficial than others in some cases

New study explains why statins are more beneficial than others in some cases

Statins' success in reducing atherosclerosis-related events has elevated the medications to wonder-drug status, with some researchers advocating for their wider use as a preemptive therapy for cardiovascular disease. [More]
Researchers identify potential drug target to fight TB

Researchers identify potential drug target to fight TB

The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target -- a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation. [More]
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands. [More]
New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT). [More]
Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine. [More]
Proteins responsible for controlling iron levels in the body also fight against infection

Proteins responsible for controlling iron levels in the body also fight against infection

Proteins responsible for controlling levels of iron in the body also play an important role in combatting infection, according to a study published today in Cell Host & Microbe. [More]
Activating bacterial receptors boosts macrophage response, limits damage to spinal cord following injury

Activating bacterial receptors boosts macrophage response, limits damage to spinal cord following injury

Macrophages are cellular sentinels in the body, assigned to identify "attacks" from viruses, bacteria, or fungi and sound the alarm when they are present. However, these cells are a "double edged sword" in spinal cord injury, providing both neural repair-promoting properties and pathological functions that destroy neuronal tissue [More]
Study discovers potential link between inherited genome-wide DNA sequences and CAD

Study discovers potential link between inherited genome-wide DNA sequences and CAD

A study to examine recessively inherited genome-wide DNA sequences has for the first time discovered a potential link with Britain's biggest killer - Coronary Artery Disease (CAD). [More]
Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001. [More]
Study examines effects of intravenous glutamine on hind limb ischemia reperfusion injury

Study examines effects of intravenous glutamine on hind limb ischemia reperfusion injury

A single dose of intravenous glutamine (GLN) administered immediately after a non-lethal lower limb ischemia reduces the reperfusion inflammatory reaction locally and systemically according to a new study. [More]
Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis. [More]
Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
People who have higher HDL function experience fewer heart attacks later in life

People who have higher HDL function experience fewer heart attacks later in life

HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease. [More]
Research shows how immune system controls biological clock in times of inflammation, infection

Research shows how immune system controls biological clock in times of inflammation, infection

Researchers at Trinity College Dublin and the University of Pennsylvania have uncovered an important link between our body clock and the immune system that will have relevance to the treatment of inflammatory and infectious diseases. [More]
Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

An international team led by Weill Cornell Medical College investigators has illuminated the precise molecular steps that enable pancreatic cancer to spread to the liver -- the event that makes the most common form of the disease lethal. By understanding this process, investigators say their discovery can lead to targeted treatments that delay metastasis, and could offer clinicians a new biomarker to test for the earliest signs of pancreatic cancer. [More]
Researchers uncover major link between human body clock and immune system

Researchers uncover major link between human body clock and immune system

An important link between the human body clock and the immune system has relevance for better understanding inflammatory and infectious diseases, discovered collaborators at the Perelman School of Medicine at the University of Pennsylvania and Trinity College, Dublin. [More]
Immune system plays surprising role in the progression of Rett syndrome

Immune system plays surprising role in the progression of Rett syndrome

New research by investigators at the University of Massachusetts Medical School suggests the immune system plays an unsuspected and surprising role in the progression of Rett syndrome, a severe neurological disorder affecting children. Immune cells known as macrophages are unable to perform their normal function and are instead amplifying the disease. [More]
Advertisement
Advertisement